Viral Hemorrhagic Fever Reagents for High Containment Pathogen Research

View Product List

Leinco Technologies provides monoclonal antibodies targeting filoviruses, arenaviruses, and bunyaviruses. Validated for ELISA, plate-based assays, and the Plaque Reduction Neutralization Test (PRNT) — widely considered the gold standard in virology for measuring true neutralizing immunity, evaluating vaccine effectiveness, and diagnosing arboviruses. Beyond clinical diagnostics, these reagents are targeted for biopharma research, vaccine development, and QC release. Products are manufactured under rigorous ISO 9001:2015 and ISO 13485:2016 standards.

Filoviruses

Monoclonal antibodies for Ebola (Zaire and Bundibugyo) and Marburg virus research. Ebola clones target GP and VP40 antigens across multiple species variants, while Marburg coverage includes GP1 and VP40 targeting clones.

Arenaviruses

Lassa virus and Lymphocytic Choriomeningitis Virus (LCMV) monoclonal antibodies targeting nucleoprotein, a key diagnostic marker for early detection of Lassa fever. Coverage is particularly relevant for surveillance efforts in endemic regions of West Africa.

Bunyaviruses

A portfolio of monoclonal antibodies spanning multiple antigen targets for Rift Valley Fever (RVFV) virus and Hantavirus (Sin Nombre and Andes). RVFV coverage includes Gc and Gn glycoproteins as well as nucleoprotein, while Hantavirus clones target viral glycoprotein.